Department of Cardiology and Intensive Care Medicine, University hospital OWL of Bielefeld University, Campus Klinikum Bielefeld, Teutoburger Str. 50, 33604, Bielefeld, Germany.
Department of Digital Medicine, Medical Faculty OWL, Bielefeld University, Bielefeld, Germany.
Herzschrittmacherther Elektrophysiol. 2022 Dec;33(4):373-379. doi: 10.1007/s00399-022-00888-2. Epub 2022 Aug 12.
The advances in health care technologies over the last decade have led to improved capabilities in the use of digital health applications (DiHA) for the detection of atrial fibrillation (AFib). Thus, home-based remote heart rhythm monitoring is facilitated by smartphones or smartwatches alone or combined with external sensors. The available products differ in terms of type of application (wearable vs. handheld) and the technique used for rhythm detection (electrocardiography [ECG] vs. photoplethysmography [PPG]). While ECG-based algorithms often require additional sensors, PPG utilizes techniques integrated in smartphones or smartwatches. Algorithms based on artificial intelligence allow for the automated diagnosis of AFib, enabling high diagnostic accuracy for both ECG-based and PPG-based DiHA. Advantages for clinical use result from the widespread accessibility of rhythm monitoring, thereby permitting earlier diagnosis and higher AFib detection rates. DiHA are also useful for the follow-up of patients with known AFib by monitoring the success of therapeutic interventions to restore sinus rhythm, e.g. catheter ablation. Although some studies strongly suggest a potential benefit for the use of DiHA in the setting of AFib, the overall evidence for an improvement in hard, clinical endpoints and positive effects on clinical care is scarce. To enhance the acceptance of DiHA use in daily practice, more studies evaluating their clinical benefits for the detection of AFib are required. Moreover, most of the applications are still not reimbursable, although the German Digital Health Care Act (Digitale-Versorgung-Gesetz, DVG) made reimbursement possible in principle in 2019.
在过去十年中,医疗技术的进步使得数字健康应用(DiHA)在检测心房颤动(AFib)方面的能力得到了提高。因此,智能手机或智能手表单独或与外部传感器结合,就可以实现基于家庭的远程心律监测。现有的产品在应用类型(可穿戴设备与手持设备)和用于节律检测的技术(心电图[ECG]与光电容积脉搏波描记法[PPG])方面存在差异。基于 ECG 的算法通常需要额外的传感器,而 PPG 则利用智能手机或智能手表中集成的技术。基于人工智能的算法可实现 AFib 的自动诊断,从而为基于 ECG 和 PPG 的 DiHA 提供高诊断准确性。由于节律监测的广泛可及性,临床应用具有优势,从而可以更早地诊断和提高 AFib 的检出率。DiHA 还可用于监测治疗干预以恢复窦性心律(例如导管消融术)的效果,从而对已知 AFib 的患者进行随访。尽管一些研究强烈表明 DiHA 在 AFib 环境中使用具有潜在益处,但关于改善硬终点和对临床护理产生积极影响的总体证据仍然很少。为了提高 DiHA 在日常实践中的接受度,需要更多研究来评估它们在检测 AFib 方面的临床益处。此外,尽管德国数字医疗保健法案(Digitale-Versorgung-Gesetz,DVG)在 2019 年原则上允许报销,但大多数应用仍不可报销。